$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
曲美替尼在日本吉西他滨难治性晚期胆道癌患者中的疗效和安全性
2025-10-19 11:44:20
Check Details
曲美替尼+达拉非尼后伊匹单抗治疗黑色素瘤完全反应但出现胃肠道毒性
2025-10-19 11:44:20
Check Details
曲美替尼+达拉非尼治疗BRAF V600E突变低级别浆液性卵巢癌患者
2025-10-19 11:44:20
Check Details
曲美替尼+达拉非尼用于BRAFV600E突变黑色素瘤:治疗停止后长期完全反应
2025-10-19 11:44:20
Check Details
曲美替尼+达拉非尼治疗BRAF V600E突变MSI-H高转移性子宫内膜癌患者
2025-10-19 11:44:20
Check Details
曲美替尼+二甲双胍治疗化疗难治性卵巢透明细胞癌患者:高通量测序的应用
2025-10-19 11:44:20
Check Details
曲美替尼+达拉非尼治疗BRAF V600E突变胆管癌:个性化精准医疗
2025-10-19 11:44:20
Check Details
曲美替尼治疗NRAS突变复发性低疾病浆液性卵巢癌:病例报告
2025-10-19 11:44:20
Check Details
曲美替尼+达拉非尼治疗伴脑干受累的脂质肉芽肿病
2025-10-19 11:44:20
Check Details
达拉非尼说明书服法
2025-10-19 11:44:20
Check Details
达拉非尼说明书储存
2025-10-19 11:44:20
Check Details
达拉非尼多少钱一盒
2025-10-19 11:44:20
Check Details
1
2
...
263
264
265
266
267
268
269
...
4162
4163
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Zongertinib for HER2-Mutant NSCLC: First-Line ORR About 76%, Brain Metastases Controlled, Manage Diarrhea and Hepatotoxicity
2
Selpercatinib Traditional Approval for RET Fusion Solid Tumors: Weight-Based Adults, BSA-Based Pediatrics, Monitor Liver, BP, QT
3
Atezolizumab Plus mFOLFOX as Adjuvant Therapy for Stage III dMMR Colon Cancer: ATOMIC DFS HR 0.50
4
Tucatinib Plus Trastuzumab and Pertuzumab Maintenance in HER2-Positive Advanced Breast Cancer: HER2CLIMB-05 Median PFS 24.9 Months
5
Zenocutuzumab (Bizengri) for NRG1 Fusion Solid Tumors: HER2×HER3 Bispecific, 750mg Q2W, NSCLC/Pancreas/Cholangiocarcinoma
6
Pemigatinib for FGFR2 Cholangiocarcinoma and FGFR1 Hematologic Use: First-Line Data, 21-Day Dosing, Phosphate and Ocular Management
7
Dabrafenib (Tafinlar) Complete Guide: Indications, Dosing, Combination Therapy and Safety
8
Binimetinib plus Encorafenib for BRAF‑Mutant Melanoma
9
Adagrasib (Krazati) for KRAS G12C: NSCLC Dosing, Titration, and CRC Regulatory Update
10
Ceritinib for ALK-Positive NSCLC: Indication, Dosing, and Safety Management
11
Enzalutamide for Prostate Cancer: Managing Fatigue, Dizziness, Hypertension, and Serious Neurocardiovascular Risks
12
Tamoxifen Long-Term Safety: Vigilance for Thrombosis and Endometrial Risks